Filing Flows › Crispr Therapeutics AG (CRSP) › Stock forecast & fair value
Crispr Therapeutics AG (CRSP) stock forecast and price target
Crispr Therapeutics AG (CRSP) trades at $50.07. 19 analysts' median price target is $80.00 (+60%), from $44.00 to $291.00.
Crispr Therapeutics AG's latest quarter
Crispr Therapeutics AG, Q3 2026: revenue $12.7M (14× year over year), net loss $111M, operating cash flow −$89.7M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for CRSP stock?
The median of 19 analysts' 12-month targets is $80.00, +60% from $50.07; the range is $44.00 to $291.00. The average rating is buy.
Does Crispr Therapeutics AG usually beat earnings estimates?
It beat the consensus EPS estimate in 40% of the quarters on record.
Is CRSP stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.